FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Klein Lawrence Otto					2. Issuer Name and Ticker or Trading Symbol <u>Dyne Therapeutics</u> , <u>Inc.</u> [DYN]						(Ch	Relationship of Reporting P (Check all applicable) X Director			erson(s) to Issuer 10% Owner	
(Last) C/O DYI	`	rst) PEUTICS, INC	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 05/26/2021							Officer below)	(give title		Other (specifically below)	pecify
830 WINTER STREET				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable					
(Street) WALTH	AM M	A	02451								Line	X Form f	led by One led by More	•	Ü	
(City)	(S		(Zip)													
		Tab	le I - Non-E	Derivativ	e Se	curities	s Ac	quired, Di	sposed o	f, or Be	neficiall	y Owned				
Date				. Transactio Date Month/Day/\	Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) 5)				Beneficia	s ally ollowing	6. Owner Form: Di (D) or Ind (I) (Instr.	rect direct E	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
						Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)		"	1113(1.4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	e Execution Date, Transact						ate	7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y Ov Fo Dii or (I)	vnership vrm: rect (D) Indirect (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$19.56	05/26/2021		A		19,596		(1)	05/25/2031	Common Stock	19,596	\$0.00	19,596		D	

Explanation of Responses:

1. This option was granted on May 26, 2021. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 26, 2022 or (ii) the date of the Issuer's 2022 Annual Meeting of Stockholders

Remarks:

/s/ Richard Scalzo, Attorney-in-05/27/2021 Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).